Biogen Inc. (Nasdaq: BIIB) and Bio-Thera Solutions, Ltd. (688177.SH) today announced results from the Phase 3 study of BAT1806, a proposed biosimilar referencing ACTEMRA®/RoACTEMRA® (tocilizumab). The study met its primary endpoints, demonstrating equivalence to the reference medicine in patients with moderate to .
The comparative study met its primary endpoints and showed equivalent efficacy and comparable safety profile in patients with moderate-to-severe rheumatoid arthritisCAMBRIDGE, Mass. and GUANGZHOU, China
Biogen Inc.; Envisagenics: Biogen and Envisagenics Announce Collaboration to Advance RNA Splicing Research
As part of the agreement, Biogen will leverage Envisagenics AI platform with the goal of better understanding Central Nervous System diseases
CAMBRIDGE, Mass. and NEW YORK, May 13, 2021today announced a new collaboration to advance ribonucleic acid (RNA) splicing research within central nervous system (CNS) diseases. As part of the collaboration, Biogen will leverage Envisagenics proprietary artificial intelligence (AI)-driven RNA splicing platform, SpliceCore
, to define and understand the regulation of different RNA isoforms in CNS cell types.
Genetic information encoded in the human chromosome is converted into RNA molecules which is then used as the template to make proteins. RNA splicing is the process that trims out extra information embedded in the intermediate RNA molecules, and this trimmed RNA is what is then used to produce functional proteins.
Biogen Announces Exercise of Option to Acquire the Investigational Drug TMS-007 for Acute Ischemic Stroke Based on Positive Phase 2a Data - read this article along with other careers information, tips and advice on BioSpace